当前位置: X-MOL 学术Chem. Soc. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers.
Chemical Society Reviews ( IF 46.2 ) Pub Date : 2020-07-06 , DOI: 10.1039/d0cs00107d
Kayoung Kim 1 , Chang Heon Lee , Chan Beum Park
Affiliation  

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and affects more than 10% of the population aged over 65 worldwide. Despite considerable global efforts, AD patients can only be diagnosed after the onset of symptoms based on neuropsychological tests and neuroimaging. Because the changes in the levels of biomarkers associated with Aβ deposits and tau tangles precede the appearance of the first cognitive symptoms, accurate measurements of AD core biomarkers is critical for identifying asymptomatic AD patients and predicting disease progression. In this regard, significant efforts have been made to develop novel AD biomarker-targeting sensor platforms that have superb sensitivity and high accessibility. This review provides an overview of recent advances in optical and electrical sensing of core AD biomarkers in clinically relevant fluids such as the cerebrospinal fluid and human blood. We have summarized current challenges and future strategies for translating the sensing techniques discovered in the academic laboratories into clinical analytic platforms for early diagnosis of AD.

中文翻译:

化学传感平台,用于检测痕量水平的阿尔茨海默氏症的核心生物标志物。

阿尔茨海默氏病(AD)是最普遍的神经退行性疾病,影响全球65岁以上的人口的10%以上。尽管做出了巨大的全球努力,但只能根据神经心理学测试和神经影像学诊断出症状发作后才能诊断出AD患者。由于与Aβ沉积物和tau缠结相关的生物标志物水平的变化先于最初的认知症状出现,因此对AD核心生物标志物的准确测量对于识别无症状AD患者和预测疾病进展至关重要。在这方面,已经做出巨大的努力来开发新颖的,以超高灵敏度和高可及性为目标的以AD生物标志物为目标的传感器平台。这篇综述概述了临床相关液体(如脑脊髓液和人血)中核心AD生物标志物的光学和电学传感的最新进展。我们已经总结了将学术实验室中发现的传感技术转化为用于AD早期诊断的临床分析平台的当前挑战和未来策略。
更新日期:2020-08-04
down
wechat
bug